The 10-day moving average for FATE crossed bullishly above the 50-day moving average on November 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 02, 2023. You may want to consider a long position or call options on FATE as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
FATE moved above its 50-day moving average on November 14, 2023 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FATE advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for FATE moved out of overbought territory on November 07, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where FATE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
FATE broke above its upper Bollinger Band on November 02, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FATE entered a downward trend on November 01, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.558) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (329.780).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical stage biopharmaceutical company
Industry Biotechnology
A.I.dvisor indicates that over the last year, FATE has been loosely correlated with GRPH. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then GRPH could also see price increases.
Ticker / NAME | Correlation To FATE | 1D Price Change % | ||
---|---|---|---|---|
FATE | 100% | +10.96% | ||
GRPH - FATE | 66% Loosely correlated | -4.24% | ||
ATAI - FATE | 54% Loosely correlated | +5.56% | ||
NBRVF - FATE | 53% Loosely correlated | N/A | ||
CVAC - FATE | 52% Loosely correlated | +0.18% | ||
OCUL - FATE | 51% Loosely correlated | +2.69% | ||
More |
Ticker / NAME | Correlation To FATE | 1D Price Change % |
---|---|---|
FATE | 100% | +10.96% |
FATE (undefined stocks) | 97% Closely correlated | +3.36% |
biotechnology (undefined stocks) | 34% Loosely correlated | +0.27% |
biopharmaceuticals (undefined stocks) | 29% Poorly correlated | +0.87% |
drugs (undefined stocks) | 26% Poorly correlated | +0.28% |